Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
High abuse potential with significant risk of psychological dependence, reported as more likely to produce dependence than other dissociatives. Compulsive redosing is a notable problem, particularly with intranasal and vaporized routes of administration due to faster onset and offset. Multiple reports document users becoming seriously dependent on this substance.
Physical dependence can develop with chronic use. Cravings and withdrawal effects may occur upon sudden cessation.
The exact toxic dosage is unknown due to limited research. As of 2022, two deaths have been attributed to 3-MeO-PCP alone (one in Sweden, one in the UK), with 14 additional deaths where the substance was detected post-mortem alongside other factors. One case involving a very large oral dose (300-500 mg) resulted in psychosis and aggressive behavior followed by amnesia, but the individual survived.
Repeated and excessive use over extended periods may cause bladder and urinary tract problems similar to those seen with ketamine, though potentially to a lesser extent due to lower quantities needed for effect; symptoms can include urinary frequency, urgency, pelvic pain, hematuria, and incontinence.
Acute cardiovascular effects include increased blood pressure and heart rate during intoxication, reported as more pronounced than with other dissociatives; abnormal heartbeat has also been reported.
Frequent use or high doses may cause neurotoxicity, as reported for arylcyclohexylamine class dissociatives generally; acute effects include confusion, disorientation, and cognitive impairment.
Respiratory depression has been reported at heavier dosage levels.
Reported to cause psychosis, delusions, and mania at significantly higher rates than other dissociatives such as ketamine, MXE, or diphenidine. A large number of experience reports describe psychotic delirium, amnesia, mania, and other serious consequences. Episodes typically occur during the offset but can emerge during onset. Hospitalization is sometimes required, with resolution occasionally taking a week or more. Risk factors include high doses, multi-day use, compulsive redosing, sleep deprivation, and chronic daily use even at low doses over weeks or months.
The extent to which seizures can occur is unknown, but they may happen in predisposed individuals, particularly under physically taxing conditions such as dehydration, fatigue, or undernourishment.
3-MeO-PCP was first synthesized in 1979 by Geneste and colleagues during an investigation into phencyclidine derivatives. This work followed earlier research by Maddox et al. in 1965, which had produced the related compounds 2-MeO-PCP and 4-MeO-PCP as part of an exploration into potential central…
Captured under broad drug analogue laws at both federal and state levels. As PCP is a Schedule 9 prohibited substance, 3-MeO-PCP is similarly prohibited as a structural analogue.
Added to Portaria SVS/MS nº 344 on May 17, 2018. Possession, distribution, and use are prohibited.
Controlled under Ley 20000 (Ley de drogas). As an ether of PCP, 3-MeO-PCP falls under the prohibition of all PCP esters and ethers specified in Chilean drug law.
As of August 25, 2015, all MeO-PCP isomers including 3-MeO-PCP were added to the list of controlled substances.
Listed as a Schedule I controlled substance under Italian drug legislation. Possession, production, and distribution are prohibited.
Not specifically controlled as 3-MeO-PCP is neither a salt nor an isomer of PCP under Portuguese drug legislation. Standard decriminalization policies for personal drug use may apply.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.
Controlled under the Misuse of Drugs Act 1971. Covered by the arylcyclohexylamine generic clause (S.I. 2013/239) which came into effect on February 26, 2013. This clause prohibits derivatives of 1-phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group and further substituted in the phenyl ring with an alkoxy substituent.
Controlled under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are prohibited.
Controlled under the Controlled Drugs and Substances Act as a PCP analogue. The CDSA places all PCP analogues, derivatives, and salts under Schedule I prohibition, making 3-MeO-PCP automatically banned despite not being mentioned by name.
Became a scheduled substance effective October 1, 2015 under Government Decree no. 243/2015 Coll., which amended Government Regulation no. 463/2013 Coll.
Added to Anlage II of the Betäubungsmittelgesetz on November 21, 2015. Production, sale, and possession are prohibited.
Listed as a Schedule I controlled substance under the Dutch Opium Act. Possession, production, and distribution are prohibited.
The Swedish public health agency recommended classification as a hazardous substance on November 10, 2014. On January 16, 2015, 3-MeO-PCP was officially declared a controlled substance.
Classified as a controlled drug. Possession, production, supply, and importation are prohibited.
Not a federally scheduled substance. However, due to structural and pharmacological similarities to the Schedule II drug PCP, possession or distribution for human consumption could be prosecuted under the Federal Analogue Act. Virginia has specifically scheduled 3-MeO-PCP as a Schedule I substance under Code of Virginia 54.1-3446.
16 sources cited
